Novel treatments targeting immune‐related mechanisms in primary biliary cholangitis
Marco Carbone, Pietro Invernizzi – 30 November 2016
Marco Carbone, Pietro Invernizzi – 30 November 2016
Marcelo Kugelmas, Mitchell Shiffman – 30 November 2016
Romina Fiorotto, Mario Strazzabosco – 30 November 2016
Mariya L. Samoylova, Kenneth E. Covinsky, Marta Haftek, Selena Kuo, John P. Roberts, Jennifer C. Lai – 24 November 2016 – Cirrhosis leads to sarcopenia and functional decline that can severely impact one's ability to function at home and in society. Self‐reported disability scales to quantify disability—Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)—are validated to predict mortality in older adults.
Davide Ghinolfi, Laura Caponi, Lorella Marselli, Daniele Pezzati, Maria Franzini, Paolo De Simone, Vanna Fierabracci, Piero Marchett, Aldo Paolicchi, Franco Filipponi – 24 November 2016
Marco Laudo, Matteo Ravaioli, Gaetano Manna, Giorgia Comai, Matteo Cescon, Massimo Gaudio, Valentina Bertuzzo, Chiara Zanfi, Alessandro Cucchetti, Antonio Daniele Pinna – 24 November 2016
Elisabeth M. G. de Vries, Manon de Krijger, Martti Färkkilä, Johanna Arola, Peter Schirmacher, Daniel Gotthardt, Benjamin Goeppert, Palak J. Trivedi, Gideon M. Hirschfield, Henriette Ytting, Ben Vainer, Henk R. van Buuren, Katharina Biermann, Maren H. Harms, Olivier Chazouilleres, Dominique Wendum, Astrid D. Kemgang, Roger W. Chapman, Lai Mun Wang, Kate D. Williamson, Annette S. H. Gouw, Valerie Paradis, Christine Sempoux, Ulrich Beuers, Stefan G. Hübscher, Joanne Verheij, Cyriel Y.
Xiaohua Chen, Odgerel Oidovsambuu, Ping Liu, Rosslyn Grosely, Menashe Elazar, Virginia D. Winn, Benjamin Fram, Zhang Boa, Hongjie Dai, Bekhbold Dashtseren, Dahgwahdorj Yagaanbuyant, Zulkhuu Genden, Naranbaatar Dashdorj, Andreas Bungert, Naranjargal Dashdorj, Jeffrey S. Glenn – 23 November 2016 – Hepatitis delta virus (HDV) causes the most severe form of human viral hepatitis. HDV requires a hepatitis B virus (HBV) coinfection to provide HDV with HBV surface antigen envelope proteins.
Matthew J. Klebanoff, Kathleen E. Corey, Jagpreet Chhatwal, Lee M. Kaplan, Raymond T. Chung, Chin Hur – 23 November 2016 – Nonalcoholic steatohepatitis (NASH) affects 2%‐3% of the US population and is expected to become the leading indication for liver transplantation in the next decade. Bariatric surgery may be an effective but expensive treatment for NASH. Using a state‐transition model, our analysis assessed the effectiveness and cost‐effectiveness of surgery to manage NASH.
Lindsey Kennedy, Heather Francis – 23 November 2016